Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRONTIER 4 long-term Mim8 prophylaxis study in haemophilia A
NL-OMON60895Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of denecimig in hemophilia A (3 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment-emergent adverse events. Started Feb 2023; status: recruiting.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON60895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60895.